EGFR and non-small cell lung carcinoma: From March 2017 to May 2019, a total of 21 NSCLC patients with a confirmed EGFR mutation at biopsy (OncomineTM NGS, as per standard of care) were consented for participation in this longitudinal study (Table 1).